Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297042 | 0.91 | TBXAS1 (0.51) | SMN1; SMN2TERTTBXAS1NAMPTMEN1 | |
| SCHEMBL8278814 | 0.88 | TBXAS1 (0.48) | TERTTBXAS1NAMPTMTNR1AMTNR1B | |
| Treamid SCHEMBL17483104 | 0.84 | TBXAS1 (0.54) | TERTTBXAS1NAMPTMEN1KMT2A | |
| SCHEMBL29145873 | 0.83 | FPR2 (0.51) | SMN1; SMN2TERTTBXAS1HTR1ATAAR1 | |
| SCHEMBL9081976 | 0.83 | TERT (0.53) | SMN1; SMN2TERTTBXAS1NAMPTMEN1 | |
| SCHEMBL7426540 | 0.81 | TERT (0.54) | SMN1; SMN2TERTTBXAS1NAMPTTAAR1 | |
| SCHEMBL9999615 | 0.81 | CYP3A4 (0.54) | TERTTBXAS1NAMPT | |
| SCHEMBL28308832 | 0.80 | TERT (0.46) | TERTTBXAS1NAMPTFPR2 | |
| SCHEMBL13034815 | 0.79 | TERT (0.49) | TERTTBXAS1NAMPTKMT2AFPR2 | |
| SCHEMBL434372 | 0.79 | TERT (0.49) | TERTTBXAS1NAMPTHTR1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885TERT 488/4885TBXAS1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.